4//SEC Filing
Andrews Timothy K. 4
Accession 0001562180-19-000147
CIK 0001656328other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 6:13 PM ET
Size
15.2 KB
Accession
0001562180-19-000147
Insider Transaction Report
Form 4
Andrews Timothy K.
General Counsel & Secretary
Transactions
- Award
Stock Options (Right to buy)
2019-01-01+22,500→ 45,000 totalExercise: $2.32Exp: 2029-01-01→ Common Stock (22,500 underlying) - Award
Stock Options (Right to buy)
2019-01-01+22,500→ 22,500 totalExercise: $2.32Exp: 2029-01-01→ Common Stock (22,500 underlying) - Award
Common Stock
2019-01-01+45,000→ 99,653 total - Award
Stock Options (Right to buy)
2019-01-01+18,290→ 18,290 totalExercise: $2.32From: 2019-01-01Exp: 2029-01-01→ Common Stock (18,290 underlying)
Holdings
- 15,000(indirect: See Footnote)
Common Stock
- 10,000(indirect: See Footnote)
Common Stock
Footnotes (6)
- [F1]Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
- [F2]Includes a total of 2,916 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
- [F3]The shares are directly held by Steelhead Bioventures LLC, a limited liability company in which the Reporting Person holds a controlling interest.
- [F4]The shares are held directly by the Andrews Living Trust (the "Trust"), of which the Reporting Person serves as co-trustee. The Reporting Person and members of his immediate family are beneficiaries of the Trust. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock held by the Trust except to the extent of his pecuniary interest therein.
- [F5]Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- [F6]Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Documents
Issuer
Sienna Biopharmaceuticals, Inc.
CIK 0001656328
Entity typeother
Related Parties
1- filerCIK 0001711464
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 6:13 PM ET
- Size
- 15.2 KB